Novel inflammatory-nutritional prognostic index for advanced gastric cancer patients undergoing gastrectomy and prophylactic hyperthermic intraperitoneal chemotherapy

Table 1 Relationship between the death within 3 years and clinicopathological characteristics of 181 advanced gastric cancer patients

Patients’ characteristics	No death (n = 97)	Death (n = 84)	χ2 value	P value
Sex			2.376	0.123
Male	64	46
Female	33	38
Age at diagnosis, years				< 0.001
< 60	55	9	41.651
≥ 60	42	75
NRS 2002			32.887	< 0.001
< 5	44	6
≥ 5	53	78
ASA score			1.960	0.581
1	1	0
2	53	44
3	42	40
4	1	0
pT stage			38.567	< 0.001
pT3	53	9
pT4	44	75
pN stage			68.524	< 0.001
N1	64	9
N2	24	26
N3	9	49
pTNM stage			38.140	< 0.001
II	40	2
III	57	82
Pathological tumor type			0.521	0.470
Adenocarcinoma	73	67
Mucinous adenocarcinoma or signet-ring cell carcinoma	24	17
Tumor site
Cardia/fundus	1	2	1.991	0.370
Body/angulus	28	31
Antrum/pylorus	68	51
Histological grade			0.062	0.804
G2	70	62
G3	27	22
Lymphovascular invasion			39.308	< 0.001
Yes	39	72
No	58	12
Surgical procedure			2.080	0.149
Open surgery	24	29
Laparoscopic surgery	73	55
Reconstruction method			0.283	0.868
Roux-en-Y	65	59
Billroth II + Braun	30	23
Billroth I	2	2
Extent of gastric resection			0.451	0.502
Distal	66	61
Total	31	23
Heat perfusion frequency			2.897	0.235
1	9	8
2	60	42
3	28	34
BMI (kg/m2)			30.885	< 0.001
< 22.1	8	37
≥ 22.1	89	47

BMI: Body mass index; NRS 2002: Nutritional Risk Screening 2002; ASA: American Society of Anesthesiologists; TNM: Tumor-node-metastasis.